Literature DB >> 14685053

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Sophie Matheron1, Sophie Pueyo, Florence Damond, François Simon, Annie Leprêtre, Pauline Campa, Roger Salamon, Genevieve Chêne, Françoise Brun-Vezinet.   

Abstract

OBJECTIVES: To identify factors associated with clinical progression in HIV-2 infected patients.
DESIGN: French prospective cohort initiated in 1994.
METHODS: Follow-up data are collected twice a year; viral load is assessed once a year by cellular viraemia, quantitative proviral DNA and plasma RNA. A Cox proportional-hazards model was used for studying baseline factors associated with clinical progression.
RESULTS: By December 2001, 217 patients had been enrolled. At inclusion, 80%, 6% and 14% were Centers for Disease Control and Prevention (CDC) group A, B and C, respectively. Median CD4 cell count was 436 x 10(6)/l. In the 48% of positive specimens, the median plasma RNA titre was 3.0 log10 copies/ml. Mean follow-up of the 179 patients seen at least twice was 34.4 months. Of these 13 died and nine progressed to group C. Ninety-three (52%) received antiretroviral therapy during a mean of 33 months, including a protease inhibitor in 48%. The probability of remaining AIDS-free was 97% and 95% at 1 and 3 years, respectively. Independent variables associated with clinical progression were age > or = 40 years [hazard ratio (HR), 11; 95% confidence interval (CI), 1.4-91.8; P = 0.03] and plasma RNA (HR, 2.5 per additional log10 copies/ml; 95% CI, 1.3-4.7, P < 0.01). Prior group B symptoms and CD4 cell count < 200 x 10(6)/l were associated with progression to AIDS. AIDS and plasma RNA were predictive of death.
CONCLUSION: Considering the limited progression rate of HIV-2 infection, combined antiretroviral therapy should be discussed in patients with high plasma RNA titres, which threshold value remains to be defined. It is recommended in case of AIDS, CDC group B symptoms or CD4 cell count < 200 x 10(6)/l.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685053     DOI: 10.1097/00002030-200312050-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.

Authors:  Florence Damond; Gilles Collin; Diane Descamps; Sophie Matheron; Sophie Pueyo; Audrey Taieb; Pauline Campa; Antoine Benard; Geneviève Chêne; Francoise Brun-Vezinet
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.

Authors:  F Damond; A Benard; Claudia Balotta; Jürg Böni; Matthew Cotten; Vitor Duque; Bridget Ferns; Jeremy Garson; Perpetua Gomes; Fátima Gonçalves; Geoffrey Gottlieb; Bernd Kupfer; Jean Ruelle; Berta Rodes; Vicente Soriano; Mark Wainberg; Audrey Taieb; Sophie Matheron; Genevieve Chene; Francoise Brun-Vezinet
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

4.  New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.

Authors:  Mélanie Bertine; Marie Gueudin; Adeline Mélard; Florence Damond; Diane Descamps; Sophie Matheron; Fidéline Collin; Christine Rouzioux; Jean-Christophe Plantier; Véronique Avettand-Fenoel
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

5.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

6.  The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Authors:  Kevin K Ariën; Awet Abraha; Miguel E Quiñones-Mateu; Luc Kestens; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 7.  Update on human immunodeficiency virus (HIV)-2 infection.

Authors:  Omobolaji T Campbell-Yesufu; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

8.  Epidemiological and virological features of HBV infection in HIV-2 infected patients living in southeastern France.

Authors:  Philippe Colson; Mireille Henry; Anne Motte; Hervé Gallais; Jacques Moreau; Isabelle Poizot-Martin; Catherine Tamalet
Journal:  Eur J Epidemiol       Date:  2006-09-20       Impact factor: 8.082

9.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

10.  Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.

Authors:  Florence Damond; Antoine Benard; Jean Ruelle; Abraham Alabi; Bernd Kupfer; Perpetua Gomes; Berta Rodes; Jan Albert; Jürg Böni; Jeremy Garson; Bridget Ferns; Sophie Matheron; Geneviève Chene; Françoise Brun-Vezinet
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.